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Depressive symptoms, assessed using a self-report type of
questionnaire, have been associated with poor outcomes in
dialysis patients. Here we determined if depressive disorders
diagnosed by physicians are also associated with such
outcomes. Ninety-eight consecutive patients on chronic
hemodialysis underwent the Structured Clinical Interview
for Diagnostic and Statistical Manual of Mental Disorders
administered by a physician. Depression was diagnosed
in about a quarter of the patients. Associations adjusted for
age, gender, race, time on dialysis and co-morbidity were
determined using survival analysis. Using time to event
(death or hospitalization) models of analysis the hazard ratios
were 2.11 and 2.07 in unadjusted and adjusted models
respectively. The finding of poor outcome using a formal
structured physician interview suggests that a prospective
study is needed to determine whether treatment of
depression affects clinical outcomes.
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Depressive symptoms may be associated with poor outcomes
in end-stage renal disease (ESRD) patients receiving chronic
dialysis, although previous studies have been inconsistent.1
Recent studies that showed an association between depres-
sive symptoms and death were based on either retrospective
analyses of large data sets2,3 or longitudinal assessment of
depressive affect using repeated self-report depression
measures, such as the Beck Depression Inventory (BDI).4
A distinction must be made between depressive affect,
as assessed by self-report questionnaires, and a psychiatric
diagnosis of depressive disorder based on Diagnostic and
Statistical Manual of Mental Disorders, 4th edition (DSM IV)
criteria.1,5,6 High levels of somatic symptoms, such as fatigue,
poor appetite, and sleep disturbance reported by chronically
ill ESRD patients on self-administered depression scales may
be misclassified as symptoms of depression and lead to a
diagnosis of depressive disorder.4,5,7–10 The association of
poor outcomes with depression as a psychiatric disorder
based on DSM IV criteria, and independent of the
confounding effects of co-morbid illness, has not yet been
well established prospectively among ESRD patients.
We previously showed that the diagnosis of depression
based on International Classification of Diseases-9 (ICD-9)
coding was associated with increased number of hospitaliza-
tions and increased length of stay in a prevalence cohort of
1588 ESRD patients receiving outpatient hemodialysis in
Veterans Affairs facilities, independent of demographics and
co-morbidities.11 We also reported that depression was more
prevalent in patients with severe chronic kidney disease, and
was associated with mortality among a cohort hospitalized with
congestive heart failure.8 Given the excessive rate of cardio-
vascular death in patients with ESRD,12–14 and the correlation
of depression with increased cardiovascular events,15–28 it
becomes imperative to investigate whether depression diagnosis
is also associated with poor outcomes in ESRD patients.
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The purpose of our study was to investigate whether there
is an association between physician-diagnosed depression,
using the Structured Clinical Interview for DSM (SCID), a
DSM-validated psychiatric interview, and poor outcomes,
such as death or hospitalization, in patients with ESRD
treated with chronic hemodialysis, and whether the associa-
tion is independent of co-morbidity.
RESULTS
Baseline characteristics of cohort
Baseline characteristics of the cohort were previously
described.5 The cohort had a mean age of 57.2 (±13.8)
years and a mean time on dialysis of 4.1 (±3.8) years. In
total, 44% were women, 14% white and 25% were receiving
chronic dialysis at a Veterans Health Affairs (VHA) out-
patient dialysis unit. The mean number of co-morbid condi-
tions was 3.1 (±1.8). In total, 26 of 98 patients (26.7%) were
depressed and 17.3% had major depression. No patient had
suicidal ideation at the time of depression assessment.
Overall, 14 of 26 depressed patients (54%) had a prior
history of depression recorded, and 11 of 26 (42%) had
antidepressants previously prescribed at study entry. Data on
behavioral/psychiatric counseling for depression were not
collected at baseline. Intervention, defined as referral to
psychiatry, initiation of antidepressant medication, or
increasing the dose of a previously prescribed antidepressant,
was made by the patient’s primary nephrologist in 6 of 26
(23%) cases diagnosed with depression by SCID after
enrollment into the study.
There were no statistically significant differences in
baseline demographics among groups based on the presence
or absence of depression by SCID (Table 1), except that
depressed patients had a higher number of co-morbidities as
compared with those without depression (P-value¼ 0.02).
Clinical characteristics, including use of percutaneous
catheter for hemodialysis, interdialytic weight gain, Kt/V,
mean hemoglobin concentration, parathyroid hormone level,
and serum albumin concentration, were similar among
groups based on the presence or absence of depression
(Table 2). Mean number of errors on the Short Portable
Mental Status Questionnaire was also comparable between
groups, in the range of intact intellectual functioning.5
Clinical outcomes
Mean time of follow-up for death or first hospitalization
was 9.0 (±5.4) months for the entire cohort. Median time
of follow-up was 5.4 months, with an interquartile range
of 4.1–14.23 months. Median time for depressed patients
was 6.7 months, interquartile range 4.1–14.2, and for
non-depressed patients was 4.9 months, interquartile range
4.0–14.3 (Wilcoxon rank sum test P-value¼ 0.64). Fifty-two
patients had reached first event, defined as death or
hospitalization, at follow-up. In total, 3 patients were
hospitalized and subsequently died, 6 patients died without
being hospitalized, and 43 were only hospitalized. Overall,
21 of 26 depressed patients (80.8%) and 31 of 72 non-
depressed patients (43.1%) had died or were hospitalized
(w2 P-value¼ 0.001).
There were no differences between reasons for hospitaliza-
tion for the depressed vs. non-depressed. Twenty percent
of all hospitalizations were due to cardiovascular causes
(such as congestive heart failure, myocardial infarction,
percutaneous coronary intervention, or coronary artery
bypass grafting), 8.7% were access-related, 15.2% were
specifically related to infected dialysis access, and 2.2% were
due to depression.
Figure 1 is the Kaplan–Meier survival curve for the event-
free probability of death or hospitalization of the cohort
based on the presence or absence of depression as measured
using the SCID. In the unadjusted Cox proportional hazards
model, depression was associated with time to first event,
either death or hospitalization, with a hazard ratio of 2.11,
95% confidence interval (1.21–3.68). The association between
depression and first event remained statistically significant
after controlling for age, race, gender, years on dialysis, and
number of co-morbidities: hazard ratio for adjusted model
was 2.07, 95% confidence interval (1.10–3.90) (Table 3).
Other covariates that were associated with increased hazards
of death or hospitalization in the multivariate model were
female gender and total co-morbidity, hazard ratio (95%
Table 1 | Patient demographics at the time of depression
diagnosis
Demographics
Not depressed,
% (±s.d.) (n=72)
Depressed
(n=26)
Mean age (years) 57.6 (14.5) 56.4 (12.0)
Female gender 44.4 46.2
White race 11.1 23.1
Currently married 33.3 44.0
Currently employed 11.1 19.2
Listed for kidney transplant 45.1 46.1
Years on dialysis 4.1 (3.7) 4.1 (3.9)
Number of co-morbiditiesa 2.9 (1.6) 4.2 (2.2)
aSignificant P-value for comparison between depressed vs. not depressed by SCID
(Structured Clinical Interview for Diagnostic and Statistical Manual of Mental
Disorders).
Table 2 | Clinical characteristics at the time of depression
diagnosis
Characteristics
Not depressed, %
(±s.d.) (n=72)
Depresseda
(n=26)
Use of percutaneous catheter 26.4 19.2
Dry weight (kg) 81.2 (20.3) 85.4 (21.6)
Interdialytic weight gain (kg/kg
dry weight)
0.04 (0.02) 0.03 (0.01)
Mean Kt/V 1.8 (1.1) 1.7 (1.2)
Mean hemoglobin concentration
(g/100 ml)
11.9 (1.5) 11.9 (1.3)
Mean parathyroid hormone level
(pg/ml)
373.1 (484.7) 376.8 (310.3)
Mean serum albumin (g/100 ml) 3.8 (0.4) 3.7 (0.4)
aAll P-values for comparisons between depressed vs not depressed were
nonsignificant.
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confidence interval) 3.22 (1.65–6.32) and 1.34 (1.13–1.58),
respectively.
To investigate whether there was a differential effect of
clinician vs. self-report measures of depression on outcomes,
we also tested the self-report measures of depression in
survival models. We previously reported that the agreements
between SCID diagnosis and depression cutoff scores on both
the Center of Epidemiological Studies Depression Scale
(CESD) and the BDI were low to moderate, at best, with
k statistics of 0.50 and 0.40, respectively (P-valueso0.0001).5
There was a nonsignificant trend toward greater hazards of
death and hospitalization for BDI, Cognitive Depression
Inventory (CDI), and CESD scores entered continuously, as
well as BDIX14 and CESDX18 entered dichotomously into
separate Cox proportional hazards models (Table 4) without
SCID diagnosis included.
Inclusion of intervention for depression into the final Cox
model did not change the hazard ratio of depression by SCID
for the primary outcome significantly. There was, however, a
non-statistically significant trend toward decreased hazard of
first event for intervention (odds ratio 0.43, 95% confidence
interval 0.17–1.08).
DISCUSSION
This is the first report, to our knowledge, of the association
between depression diagnosed using a formal, DSM IV-
based, structured physician interview and poor outcomes in a
consecutive sample of ESRD patients treated with chronic
hemodialysis. Importantly, the increased hazard of death and
hospitalization for depression remained statistically signi-
ficant even after adjustment for age, gender, race, time of
dialysis and co-morbidities. The effects of depression on
these outcomes were, in fact, of the same order of magnitude
as medical co-morbidities. These findings add to the prior
literature that relies on the use of self-report questionnaires
for the measurement of depressive symptoms rather than
the psychiatric diagnosis.2–4,9,29–34 As shown by our data,
clinician DSM IV-based diagnosis of depression was in fact a
stronger predictor of outcomes as compared with self-report
scales, such as the CESD, BDI, or CDI.
In addition, results reported by previous studies were
inconsistent, with most studies reporting an associa-
tion,2–4,9,30,31,33–39 and a few others revealing no association
between depressive symptoms and poor outcomes.40,41 Some
of this inconsistency can be explained by the difference in
scales used to measure depressive affect vs. depressive
disorder, and sample demographic variations across studies.
For example, Drayer et al.42 reported the association of
depression with mortality in a cohort of 62 chronic
hemodialysis patients, but two-third of the patients catego-
rized as ‘depressed’ had minor depression and actually did
not meet the criteria for major depressive disorder. Selection
bias may have further confounded this study as recruitment
was not done consecutively. Instead, dialysis staff suggested
patients for the study to the investigators who then screened
those select patients for enrollment, perhaps resulting in the
inclusion of sicker, more challenging patients who would
have a greater propensity for poor outcomes.42
A more tenable explanation for inconsistency of previous
reports could be the proximity of depression measurement to
the time of outcome assessment, as well as the persistence of
depressive symptoms over time. For example, Kimmel et al.4
reported that although baseline level of depressive symptoms
by BDI in 295 urban chronic dialysis patients was not a signi-
ficant predictor of mortality, when depression was treated
as a time-varying covariate based on periodic follow-up, the
Table 4 | Cox proportional hazards model for first eventa
Main independent variable Unadjusted modelb Adjusted modelb,c
BDI score, per unit increase 1.03 (0.99–1.07) 1.01 (0.96–1.05)
CDI score, per unit increase 1.02 (0.97–1.07) 0.99 (0.94–1.05)
CESD score, per unit increase 1.03 (1.00–1.06) 1.01 (0.98–1.04)
BDI score X14 vs. o14 1.21 (0.66–2.21) 0.86 (0.45–1.64)
CESD score X18 vs. o18 1.31 (0.74–2.32) 1.06 (0.58–1.96)
Abbreviations: BDI, Beck Depression Inventory; CDI, Cognitive Depression Scale;
CESD, Center for Epidemiological Study of Depression.
aFirst event represents the composite of death or first hospitalization.
bColumns represent hazard ratios (95% confidence intervals).
cModels were adjusted for age, gender, race, time on dialysis, and co-morbidity.
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Figure 1 | Kaplan–Meier survival curve for time to first event,
either death or hospitalization. Dotted line represents patients
with depression diagnosis by SCID (Structured Clinical Interview
for Diagnostic and Statistical Manual of Mental Disorders)
and solid line represents those without depression diagnosis.
P-value for Kaplan–Meier curve is 0.007.
Table 3 | Cox proportional hazards model for first eventa
Hazard ratio (95% CI)
Unadjusted analysis
Depression diagnosis by SCID 2.11 (1.21–3.68)
Multivariate analysis
Depression diagnosis by SCID 2.07 (1.10–3.90)
Age, per year increase 0.99 (0.96–1.01)
White race 1.50 (0.70–3.22)
Female gender 3.22 (1.65–6.32)
Time on dialysis, per year increase 1.03 (0.98–1.09)
Total co-morbidity, per number increase 1.34 (1.13–1.58)
Abbreviations: CI, confidence interval; SCID, Structured Clinical Interview for
Diagnostic and Statistical Manual of Mental Disorders.
aFirst event represents the composite of death or first hospitalization.
932 Kidney International (2008) 74, 930–936
o r i g i n a l a r t i c l e SS Hedayati et al.: Depression and poor outcomes in chronic dialysis
level of depressive affect was significantly associated with
mortality in both bivariate and multivariate analyses. We
previously reported that depression diagnosis by ICD-9
coding was associated with increased cumulative hospital
days and increased number of hospitalizations, after adjust-
ing for co-morbidity, in a prevalence cohort of 1588 male
ESRD patients receiving chronic hemodialysis in VHA
facilities.11 However, baseline depression diagnosis was not
independently associated with all-cause mortality in the same
cohort during a 2-year observation period.11 Similarly, in an
analysis of observational data from the Choices for Healthy
Outcomes in Caring for End-Stage Renal Disease (CHOICE)
study, baseline high level of depressive affect was not
associated with increased overall 2-year mortality, but
persistently higher levels of depressive affect over time were
associated with increased risk of death and cardiovascular
events.3 The strength of this relationship was attenuated
when a 6-month time lag was incorporated into analyses,
leading the authors to propose that the association of
depression with outcomes is due to worsening co-morbid
illness leading to depression, rather than depression leading
to poor outcomes.3,43
This secondary analysis of the CHOICE study was limited,
however, by the use of a non-traditional measure of
depressive affect, the five-item Mental Health Subscale of
Medical Outcomes Study SF-36 self-report questionnaire, as
well as an arbitrary cutoff for a ‘high’ level of depressive
symptoms not validated in ESRD patients.3,43 The potential
existence of co-linearity between a high score on this scale
and severity of co-morbid illness may bias the reported
association with poor outcomes. In our study, the fact that
depression as a psychiatric disorder diagnosed by formal
physician interview was associated with greater hazards of
death and hospitalization, even after controlling for co-
morbidity, suggests that other mechanistic factors may
mediate depression and poor outcomes in ESRD patients.
The lack of statistically significant associations between self-
reported measures of depressive affect with poor outcomes in
this same cohort underlines the limitation of these scales for
diagnosing the presence of a defined psychiatric syndrome in
mediating clinically important outcomes in patients with
ESRD.10 Measurements of depressive affect and a psychiatric
diagnosis of a major depressive disorder are likely to yield
different results and may be associated with different
outcomes in patients with chronic illness because of the
overlap between somatic symptoms of depression and
components of the psychiatric diagnosis.1,5,44,45 In fact, few
studies have shown that baseline evaluations of depressive
affect are not associated with mortality in ESRD subjects,3,4
highlighting the importance of making a psychiatric
diagnosis in these patients. Treatment decisions similarly
will be likely different according to data generated by
different screening techniques.44,46
There is a large body of literature in non-dialysis patients
to report the strong and independent association between
depression and poor cardiovascular outcomes.15–28 It is well
established that depressive symptoms are associated with
novel cardiac events among patients without known history
of coronary artery disease15–21 and recurrent cardiac events
and death among patients with known heart disease.22–27
Although it is difficult to delineate whether depressive
disorder itself has a direct mechanistic role in the develop-
ment of cardiac events and death or whether depressive
symptoms are merely a surrogate marker for increased co-
morbidity and cardiovascular disease severity, specific
biological and behavioral factors have been proposed and
investigated as potential mechanisms by which depression
may lead to poor patient outcomes.7,10,47–64 These include
common genetic influences on depression and coronary
heart disease observed in twin studies;48,49 behavioral factors
such as non-adherence, unhealthy lifestyle, poor nutrition,
and social support in those depressed;10,50–54 altered auto-
nomic tone, such as lower heart rate variability, in patients
with recent MI and major depression;55–57 enhanced activity
of the hypothalamic–pituitary axis, such as increased cortisol
and norepinephrine excretion;58,59 and alterations in inflam-
mation and immune status.7,10,60 The most compelling
proposed mechanism is the association of altered serotonin
levels seen in depressed patients with resultant increased
platelet activation and vasoconstriction, which can then lead
to coronary events.61–64
A few limitations of this study warrant discussion. First,
although an association was shown between depression and
poor outcomes, most patients were hospitalized and did not
experience death. Although this is not unexpected, it is
difficult to draw firm conclusions from this analysis on
the independent effect of depression on mortality alone.
This study was also not powered to delineate the association
of depression with cause of hospitalization or death, such as
cardiovascular causes. Future studies are needed to investi-
gate the association of depressive disorder with cardiovas-
cular events in larger ESRD samples, using gold standards for
depression diagnosis and cardiovascular events. Second, due
to the observational nature of the study, patients were
not randomly assigned to receive intervention for depression
and the effect of treatment of depression on outcomes could
not be elucidated. Large randomized controlled studies are
needed to establish the effect of treatment of depression on
ESRD patient outcomes. Furthermore, as sample size must be
taken into consideration, failure to have found a statistically
significant association between certain clinical and demo-
graphic variables and presence of depression does not mean
that an association did not exist. Although adjustment for
several of these factors in survival analyses may have
statistically accounted for their confounding effect, such
adjustment may not fully account for their impact on
outcomes. Finally, generalizability of results is limited as the
sample was composed predominantly of African Americans,
even though a similar proportion of women and diabetics
to the prevalent ESRD US population were enrolled.12 As
African Americans have the highest prevalent rates of
ESRD,12 and depression is a salient co-morbidity for African
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Americans,65,66 it is important that African Americans be
enrolled consistently in any ongoing ESRD depression trials.5
Identifying depression in ESRD patients by formal
psychiatric interview is important given the association with
poor outcomes. Although safety and efficacy of antidepres-
sant medication was established in the general population
after acute coronary syndrome,67 there is less evidence
regarding the safety and efficacy of antidepressants in patients
with ESRD receiving chronic dialysis, especially as these
patients, as well as patients with advanced CKD not yet on
dialysis, are generally excluded from antidepressant treatment
trials. Few data that exist on antidepressant therapy of ESRD
patients were observational and included small numbers.68–70
More studies are needed to establish the safety and efficacy of
such therapies in dialysis patients and whether treatment of
depression in this group will improve outcomes.
MATERIALS AND METHODS
Study subjects
Detailed study methods have been previously described.5 In brief,
ESRD patients receiving chronic hemodialysis at outpatient units
were consecutively invited to participate. Those who were non-
English speaking (four patients) or could not sign consent due to
severe dementia and lack of health-care power of attorney (three
patients) were excluded. Patients were enrolled from March 2003 to
April 2004 after signing informed consent. Sites of enrollment
included the VHA outpatient dialysis unit and two other outpatient
units affiliated with Duke University Medical Center in Durham,
NC, USA. This study was approved by the institutional review
boards at both the Durham VHA and Duke University.
Assessment of depression
Self-report measures of depression, in addition to the 10-item Short
Portable Mental Status Questionnaire to identify dementia,71 were
administered to all patients at enrollment by the research assistant
and included the CESD, BDI, and the CDI as described before.5
The BDI is a 21-item depression scale that has been validated in
both the general population and ESRD patients for measuring the
severity of depressive symptoms.4,5,9,10,29,72,73 The CDI, which
excludes the somatic symptoms of depression, is the first 15 items
of the BDI and has been previously used to assess depressive
symptoms in ESRD subjects.4,5,7,9 The CESD, a 20-item Likert scale
for depressive symptoms, has also been validated in non-ESRD
populations.74 The SCID was used as the gold standard for the
diagnosis of depressive disorder and was administered to all patients
at study entry by the same nephrologist, who was blinded to patient
medical history and scores on self-report measures. The SCID is a
DSM IV-based structured clinical interview for the diagnosis of
depression and has been tested for reliability and validity in previous
studies.75–77 Depression was defined as a diagnosis of major
depressive disorder, dysthymia, or minor depression based on SCID.
Any diagnosis of depression or suicidal ideation was reported to
the patient’s primary nephrologist who was different from the
nephrologist administering the SCID and who assessed the patient
for safety and decided if intervention was indicated after depression
was diagnosed. Intervention was defined as referral to psychiatry,
initiation of antidepressant medication, or increasing the dose
of a previously prescribed antidepressant within 4 weeks of SCID
evaluation.
Data collection
Patient interview and medical records were used to collect
demographic and clinical data, including laboratory values, at
study entry. Co-morbidity was defined as the sum total of number
of co-morbid illnesses and included history of diabetes mellitus,
hypertension, congestive heart failure, coronary artery disease,
cerebrovascular disease, peripheral vascular disease, chronic lung
disease, non-skin cancer, human immunodeficiency virus infection,
chronic pain, psychiatric illness, illicit drug or alcohol abuse, and
current tobacco abuse. Interdialytic weight gain was calculated as
the mean of the most recent six pre-dialysis weights minus the
established dry weight, divided by dry weight.78 Kt/V was calculated
using the second-generation single-pool Daugirdas formula.79
Serum albumin concentrations that were measured at the VHA
using the bromcresol purple method were converted mathematically
to a value consistent with the bromcresol green method by
adding 0.55.80
Clinical outcomes
Patients were followed prospectively for up to 1 year after enroll-
ment. The primary outcome variable was time to first event, which
was defined as the composite of death or first hospitalization.
Hospitalizations and deaths were determined by first searching all
Duke and Durham VHA hospital patient records and then reviewing
the outpatient dialysis medical charts for outside facility hospitaliza-
tions. All hospitalizations were then confirmed with the patients,
and all deaths were confirmed with the medical point personnel at
each dialysis facility. Reason for hospitalization was ascertained for
each subject using the principal discharge diagnosis recorded from
the hospital discharge summary. Censorship took place at first event
or if the patient was alive at the time of first follow-up. The primary
analysis was to investigate the association between a diagnosis of
depression by SCID at enrollment and the primary outcome.
Secondary analyses included investigation of associations between
other measures of depressive affect, such as CESD, BDI, and CDI,
and the primary outcome.
Statistical analysis
Patient demographic and clinical characteristics were compared
among groups based on the presence or absence of depression
as defined using the SCID. For bivariate comparisons between
depression groups, categorical variables were compared using the w2
test, and continuous variables using the Student’s t-test. Kaplan–-
Meier curves and Cox proportional hazards models were used for
survival analysis, with depression by SCID as the main independent
variable. Separate survival models were constructed using BDI,
CESD, and CDI scores continuously as the main independent
variables. BDI score X14 and CESD score X18 were also analyzed
dichotomously as main independent variables in survival models.
We previously reported that these BDI and CESD cutoffs have
the best diagnostic accuracy for depression diagnosis, using the
SCID as the gold standard, in ESRD patients receiving chronic
hemodialysis.5
Time period at risk was defined as time from date of SCID
administration to first follow-up. Cox models were adjusted for age,
gender, race, years on dialysis, and number of total co-morbidities.
Although this was an observational study and patients were not
randomly assigned to receive intervention for depression, interven-
tion was entered into the final model as an independent variable to
investigate whether treatment of depression was associated with
change in clinical outcomes.
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